Lung tissue, including lung cancer and chronic lung diseases such as chronic obstructive pulmonary disease, cumulatively account for some 280,000 deaths annually; chronic obstructive pulmonary disease is currently the fourth leading cause of death in the United States 1 . Contributing to this mortality is the fact that lungs do not generally repair or regenerate beyond the microscopic, cellular level. Therefore, lung tissue that is damaged by degeneration or infection, or lung tissue that is surgically resected is not functionally replaced in vivo. To explore whether lung tissue can be generated in vitro, we treated lungs from adult rats using a procedure that removes cellular components to produce an acellular lung extracellular matrix scaffold. This scaffold retains the hierarchical branching structures of airways and vasculature, as well as a largely intact basement membrane, which comprises collagen IV, laminin, and fibronectin. The scaffold is mounted in a bioreactor designed to mimic critical aspects of lung physiology, such as negative pressure ventilation and pulsatile vascular perfusion. By culturing pulmonary epithelium and vascular endothelium within the bioreactor-mounted scaffold, we are able to generate lung tissue that is phenotypically comparable to native lung tissue and that is able to participate in gas exchange for short time intervals (45-120 minutes). These results are encouraging, and suggest that repopulation of lung matrix is a viable strategy for lung regeneration. This possibility presents an opportunity not only to work toward increasing the supply of lung tissue for transplantation, but also to study respiratory cell and molecular biology in vitro for longer time periods and in a more accurate microenvironment than has previously been possible.
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Video Link
The video component of this article can be found at https://www.jove.com/video/2651/
Protocol

Bioreactor Assembly
Detailed figure(s) of the bioreactor design and assembly for both decellularization and culture are provided in Figures 1 and 2 , respectively. All components must be sterilized prior to assembly of the bioreactor. The following specific points are noted:
CONNECTIONS:
1. The arterial cannula consists of a luer-lock fitting connected to a Y-splitter by a short segment of tubing. The luer-lock connector is attached to the perfusion tubing, and the segment of the Y that is not sutured to the pulmonary artery is connected to a one-way valve. The one-way valve is oriented such that fluid can be drawn up into the tubing (in the opposite direction as perfusion), but during organ perfusion all medium flows into the lung. 2. The tracheal cannula also consists of a luer-lock connector linked to a Y-splitter with tubing. The luer-lock connects to a breathing loop between the trachea reservoir and the main chamber. The segment of the Y-connector that is not sutured to the trachea is also connected to a one-way valve. The one-way valve is oriented in the same fashion as the arterial cannula.
FUNCTIONS:
3. The one-way valves in the arterial and tracheal cannulae are utilized to clear air bubbles in the tubing by enabling reversal of flow in the tubing and therefore permitting air bubbles to be removed. 4. The "breathing loop" includes two one-way valves, positioned such that medium follows a different path into and out of the lung. A more detailed description of this feature is provided in a prior publication from our laboratory 2 . 5. Vascular perfusion is provided using a roller pump. Medium is perfused into the pulmonary artery via the attached cannula, flows through the lung vasculature, and out the pulmonary vein directly into the main bioreactor, where medium is drawn up for perfusion. A vacuum system may be helpful to provide suction.
Organ Decellularization
Perfuse with decellularization solution until 500ml of solution has perfused through the lung. Optimal pressure is <15 mmHg (~20 cm H 2 O). This typically will require 2.5 hours. Flow rates are typically very slow (0.2-0.5ml/minute) initially, and rapidly increase during the second hour to approximately 1ml/minute or greater. Periodically, remove used decellularization fluid from bioreactor, ensuring enough fluid remains to support the lung and tracheal cannula.
Organ rinsing and sterilization
1. Transfer lung and bioreactor to a tissue culture hood. Begin rinsing with sterile PBS by removing the 500ml jar that contained the decellularization fluid and replacing with a sterile jar containing up to 1L of sterile PBS. Use vacuum suction to ensure lines are clear of air. 2. Perfuse PBS through the vasculature at 10-15 mmHg, in the same manner as for decellularization. Periodically, remove waste PBS from bioreactor and replace and/or refill the PBS jar with fresh, sterile PBS. It is advisable to use sterile technique. 3. Continue rinsing until at least 2.5 L of sterile PBS have perfused the lung. 4 . Transfer lung to a new, sterile bioreactor system containing fresh PBS. Ensure that both the entire perfusion loop and the entire airway lines are filled with fluid. All subsequent steps will use a pulsatile pump to perfuse the lungs at 5ml/min. 5. Sterilize the scaffold, either via overnight perfusion with PBS + 10% FBS + 10% pen-strep solution or for 3 hours with 0.1% peracetic acid in PBS. The latter will require rinsing the lung with 3 changes of 250ml PBS over several hours to remove residual acid. For each rinse, the lung should be ventilated as well as perfused to ensure that all parts of the tissue are rinsed thoroughly. 6. Transfer the lung to a 37°C incubator and perfuse with PBS that has 10% FBS and 10% penicillin/streptomycin for ~1hr or until temperature is equilibrated, in preparation for benzonase treatment. 7. Treat lung with benzonase to remove remnant DNA:
1. Warm the benzonase buffer (see Table of Reagents) to 37°C. 2. For each lung, fill one 10ml syringe with benzonase buffer only and one 10ml syringe with 90U/ml benzonase in buffer.
3. Stop perfusion of the lung.
4. Inflate the airway with benzonase buffer. 5. Allow the lung to deflate (for ~1 minute). Then, inflate the lung with the benzonase solution. During the inflation with benzonase buffer & benzonase, try to avoid injecting any air into the lung. 6. Allow the lung to sit without perfusion or ventilation at 37°C for 1 hour after inflating with benzonase.
8. Resume perfusion with the PBS + 10% FBS, 10% penicillin/streptomycin that is already in the bioreactor, and continue overnight. The following day, the lung can either be stored at 4°C (for up to 3 months) or prepared for cell seeding. 9. To prepare the scaffold for cellular repopulation, replace the PBS/FBS/benzonase solution with ~250ml of culture medium. Perfuse for at least one hour before cells are introduced, and replace with fresh culture medium directly before seeding cells.
Recellularization
The choice of cell source for organ reseeding is left up to individual investigators. Many cell sources can be utilized, including commercially available populations, freshly isolated neonatal or fetal pulmonary cells, embryonic stem cells, or commercially available cell sources. Specific isolation protocols for these cell populations can be found elsewhere 4, 5, 6 . Here, we provide instructions on how to seed both endothelial and epithelial cell populations.
Endothelial seeding:
1. Prepare a suspension of desired endothelial cell population, in appropriate culture medium. Filter cell suspension through a 40um cell strainer to remove cell clumps. A typical endothelial seeding in our laboratory would utilize approximately 30 million rat lung microvascular endothelial cells in 60ml of culture medium. 2. Dispense cell suspension into a small reservoir temporarily incorporated into the perfusion loop of the bioreactor (Figure 2 ). Ensure that the tubing from this reservoir and the entire perfusion loop is clear of air bubbles. 3. Infuse cells into the pulmonary artery at 3ml/min using a roller pump. 4. After cell infusion, continue perfusion with medium recirculated from the main bioreactor at desired rate. 5. On a daily basis, ensure that the perfusion tubing is clear of air bubbles. 6. Medium should be replaced with fresh medium regularly; this is often done every 3-4 days.
Epithelial seeding:
1. Prepare a cell suspension of the desired epithelial cell population. In our laboratory, this typically consists of approximately 50-100 million neonatal rat pulmonary cells. Filter the population through 40um cell strainer and suspend in 15ml of culture medium in a syringe. Fill the airway reservoir with 80ml of culture medium. 2. Place the bioreactor in a 37°C tissue culture incubator, and connect the syringe pump for ventilation. Ensure all ventilation lines are clear of air.
1. Seed the cells into the lung by injecting 15ml of cell suspension as a single bolus into the tracheal cannula. 2. Immediately begin a single, slow breath using the syringe pump. This breath is administered by withdrawing 60ml of air from the main bioreactor at 3ml/minute, thus lasting approximately 20 minutes. Ensure the air filters on the main bioreactor are capped off immediately after injecting the cell suspension and before beginning the slow breath.
3. Allow the lungs to sit statically for approximately 18hrs, and then begin slow vascular perfusion (approximately 0.5 ml/min).
Organ Culture
Although the details of perfusion and ventilation will vary based on experimental design, the following points are noted:
1. During endothelial culture, perfusion is typically performed at 1-3 ml/min using a roller pump. During epithelial culture, ventilation is typically provided at a continuous rate of 1 breath per minute using a syringe pump. Withdrawal of 5-10ml of air from the main bioreactor is typically required to effect lung ventilation at a normal tidal volume. Due to the need to maintain the bioreactor airtight during ventilation, ventilation should be paused daily and the air in the main chamber should be exchanged. All air in the system is room air, which is approximately 21% oxygen by partial pressure. The 5-10ml withdrawal of air from the bioreactor (which induces a 5-10ml inspiration of fluid by the lung) is based on the size of the lung and how many lobes are being cultured (lobes can be tied off for analysis, while the remaining lobes continue in culture). The amount of air withdrawn by the syringe pump is chosen to approximate the "tidal volume" of the cultured lung. 2. Medium should be changed approximately every 3-4 days during culture. 3. During co-culture of both epithelium and endothelium, experiments in our laboratory typically first seed the epithelium for 4-8 days, during which time the engineered tissue is ventilated. The endothelium is then seeded via perfusion, after which the tissue is both perfused and ventilated.
Repopulation of acellular matrix and culture of lung tissue
If cells are freshly isolated from 7 day old neonatal rat pups, as described in the online supplement accompanying the work by Petersen and colleagues 4 , one can expect a cell yield of 120-150 millions cells per litter of 10 pups (just over 10 million cells per neonate).
Optimal conditions for cell seeding and subsequent culture of the lung in the bioreactor should yield well-distributed cells within all 5 lobes of the lung, and should provide coverage of approximately 70% of the extracellular matrix scaffold (Figure 3 ). The cultured cell population will be positive for key respiratory cell markers such as pro-secretory protein-C (SPC), Clara cell secretory protein (CCSP), and aquaporin-5 (AQP), in order of relative abundance (Figure 4 ). 
Discussion
The most critical aspects of the system presented here include maintenance of sterility, and close monitoring of pressures applied to the vascular bed throughout the process of preparing and seeding the scaffold and culturing the repopulated lung. Sterility is best maintained by autoclaving all materials prior to use, and by mounting the lung in a closed system shortly after explant and avoiding subsequent breach of this barrier. After the decellularized matrix has been thoroughly rinsed and transferred to a sterile bioreactor for culture, the silicone cap and other seals and connections should not be disturbed or removed. To keep pressures in check, flow driven by gravity is preferable whenever possible. When a pump is required for recirculation of fluid, beginning after rinsing with PBS and continuing during culture, we recommend directly measuring the pressure just before the fluid enters the pulmonary artery with a pressure transducer. The magnitude of the applied pressure should not exceed 15 mm Hg.
Recellularized lungs can be cultured for varying time periods, typically ranging from 4 days to up to 3 weeks. Vascular perfusion is typically accomplished at 1-3 ml/min during endothelial culture, while ventilation is typically applied at a rate of 1 breath/min during epithelial culture. During combined culture periods, simultaneous ventilation and perfusion is appropriate. Ventilation can be performed with either liquid medium or air.
Over the course of the last several decades, several groups have done important tissue engineering work showing the feasibility of differentiating lung epithelium in vitro and of replicating several aspects of lung microanatomy 7, 8, 9, 10 . However, until recently, 4,5 none of these attempts to engineer lung tissue had resulted in an implantable organ that was able to maintain separation between the blood and airway compartments and that could participate in gas exchange. Therefore, though the methods described are only an initial step toward the long-term goal of generating functional lung tissue, this work is an encouraging step toward the possibility of increasing the amount of lung tissue available for transplant. Moreover, this work elaborates work done by Ott et al. and Uygun and colleagues 11, 12 , demonstrating the efficacy of a decellularized extracellular matrix as a scaffold for tissue engineering complex three-dimensional structures and supporting the growth and survival of various types of cells. This work is also significant for its contribution to the armamentarium of respiratory cell and molecular biologists. By providing a unique, three-dimensional environment that can also provide appropriate mechanical stimuli, and that does not share the attendant hazard of rapid dedifferentiation that one might encounter when culturing rodent epithelium in the laboratory with more traditional methods 13 ,scientists could use our system to gain new insight into cell-cell and cell-matrix interactions that play a role in cell differentiation and function. This knowledge may be particularly powerful if used as leverage to guide the fate of various stem cell populations, as Cortiella's group has demonstrated in initial studies 14 .
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